Unlocking the Mysteries of Diabetic Retinopathy

Published on August 16, 2022

Imagine if your body was a bustling city, and one area in particular was experiencing some serious issues. That’s what happens in diabetic retinopathy, a condition where persistently high blood sugar levels not only damage tiny blood vessels in the eyes, but also create inflammation and degeneration of the nerve cells. It’s like a domino effect of trouble! Despite our increasing understanding of the disease, current treatments mainly focus on its late-stage complications and target a single molecule called vascular endothelial growth factor (VEGF). But researchers are diving into the depths of neuroinflammation and neurodegeneration in diabetes, studying human subjects, developing imaging biomarkers, and exploring new therapeutic options. By unraveling these mysteries, we may be able to discover groundbreaking treatments that can intervene earlier and prevent further damage to the delicate neural network in our eyes. Want to learn more? Check out the research!

Diabetic retinopathy (DR) is the most common complication of diabetes and has been historically regarded as a microangiopathic disease. Now, the paradigm is shifting toward a more comprehensive view of diabetic retinal disease (DRD) as a tissue-specific neurovascular complication, in which persistently high glycemia causes not only microvascular damage and ischemia but also intraretinal inflammation and neuronal degeneration. Despite the increasing knowledge on the pathogenic pathways involved in DR, currently approved treatments are focused only on its late-stage vasculopathic complications, and a single molecular target, vascular endothelial growth factor (VEGF), has been extensively studied, leading to drug development and approval. In this review, we discuss the state of the art of research on neuroinflammation and neurodegeneration in diabetes, with a focus on pathophysiological studies on human subjects, in vivo imaging biomarkers, and clinical trials on novel therapeutic options.

Read Full Article (External Site)

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes:

<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>